Patents by Inventor Gene Hung
Gene Hung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190017047Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.Type: ApplicationFiled: May 7, 2018Publication date: January 17, 2019Applicants: Ionis Pharmaceuticals, Inc., University of Utah Research FoundationInventors: C. Frank Bennett, Susan M. Freier, Stefan M. Pulst, Daniel R. Scoles, Gene Hung
-
Publication number: 20180273945Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: ApplicationFiled: October 5, 2017Publication date: September 27, 2018Applicants: Ionis Pharmaceuticals, Inc., CHDI Foundation, Inc.Inventors: Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
-
Patent number: 10006027Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism. Provided are methods for reducing expression of Ataxin 2 (ATXN2) mRNA and protein in an animal. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases, including spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism by inhibiting expression of Ataxin 2 in an animal.Type: GrantFiled: March 19, 2015Date of Patent: June 26, 2018Assignees: Ionis Pharmaceuticals, Inc., University of Utah Reseach FoundationInventors: C. Frank Bennett, Susan M. Freier, Stefan M. Pulst, Daniel R. Scoles, Gene Hung
-
Publication number: 20180087052Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.Type: ApplicationFiled: May 16, 2017Publication date: March 29, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
-
Patent number: 9926559Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.Type: GrantFiled: January 9, 2014Date of Patent: March 27, 2018Assignee: Biogen MA Inc.Inventors: C. Frank Bennett, Gene Hung, Frank Rigo
-
Patent number: 9717750Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.Type: GrantFiled: February 9, 2015Date of Patent: August 1, 2017Assignees: Biogen MA Inc., Cold Spring Harbor LaboratoryInventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger
-
Publication number: 20170175113Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism. Provided are methods for reducing expression of Ataxin 2 (ATXN2) mRNA and protein in an animal. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases, including spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism by inhibiting expression of Ataxin 2 in an animal.Type: ApplicationFiled: March 19, 2015Publication date: June 22, 2017Applicants: Ionis Pharmaceuticals, Inc., University of Utah Research FoundationInventors: C. Frank Bennett, Susan M. Freier, Stefan M. Pulst, Daniel R. Scoles, Gene Hung
-
Publication number: 20170175114Abstract: Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.Type: ApplicationFiled: March 19, 2015Publication date: June 22, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Gene Hung, C. Frank Bennett
-
Patent number: 9683236Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.Type: GrantFiled: January 25, 2016Date of Patent: June 20, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
-
Publication number: 20170015995Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.Type: ApplicationFiled: February 9, 2015Publication date: January 19, 2017Applicants: Ionis Pharmaceuticals, Inc., Cold Spring Harbor LaboratoryInventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger
-
Patent number: 9523094Abstract: Certain embodiments are directed to methods of ameliorating, treating, or preventing Kennedy's Disease in a subject carrying a mutation in the Androgen Receptor (AR) gene, such as expansion of a CAG trinucleotide repeat, which is associated with Kennedy's Disease, by administering an antisense compound targeted to AR. Several embodiments provided herein relate to the discovery that antisense compounds targeting Androgen Receptor can ameliorate, treat, or prevent Kennedy's Disease in a subject carrying a mutation in the Androgen Receptor gene, such as expansion of a CAG trinucleotide repeat, which is associated with Kennedy's Disease.Type: GrantFiled: October 11, 2013Date of Patent: December 20, 2016Assignee: Ionis Pharmaceuticals, Inc.Inventor: Gene Hung
-
Publication number: 20160312217Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.Type: ApplicationFiled: January 25, 2016Publication date: October 27, 2016Applicant: Ionis Pharmaceuticals, Inc.Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
-
Patent number: 9273315Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.Type: GrantFiled: October 30, 2014Date of Patent: March 1, 2016Assignee: Ionis Pharmaceuticals, Inc.Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
-
Publication number: 20160053256Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: ApplicationFiled: May 11, 2015Publication date: February 25, 2016Applicants: CHDI FOUNDATION INC., ISIS PHARMACEUTICALS, INC.Inventors: Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
-
Publication number: 20160002627Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.Type: ApplicationFiled: January 9, 2014Publication date: January 7, 2016Applicant: Isis Pharmaceuticals. Inc.Inventors: C. Frank Bennett, Gene Hung, Frank Rigo
-
Publication number: 20150284725Abstract: Certain embodiments are directed to methods of ameliorating, treating, or preventing Kennedy's Disease in a subject carrying a mutation in the Androgen Receptor (AR) gene, such as expansion of a CAG trinucleotide repeat, which is associated with Kennedy's Disease, by administering an antisense compound targeted to AR. Several embodiments provided herein relate to the discovery that antisense compounds targeting Androgen Receptor can ameliorate, treat, or prevent Kennedy's Disease in a subject carrying a mutation in the Androgen Receptor gene, such as expansion of a CAG trinucleotide repeat, which is associated with Kennedy's Disease.Type: ApplicationFiled: October 11, 2013Publication date: October 8, 2015Applicant: Isis Pharmaceuticals, Inc.Inventor: Gene Hung
-
Patent number: 9057066Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: GrantFiled: December 7, 2012Date of Patent: June 16, 2015Assignees: Isis Pharmaceuticals, Inc., CHDI Foundation Inc.Inventors: Gene Hung, Janet M. Leeds, C. Frank Bennett, Susan M. Freier
-
Publication number: 20150159155Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.Type: ApplicationFiled: October 30, 2014Publication date: June 11, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
-
Patent number: 8980853Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.Type: GrantFiled: June 17, 2010Date of Patent: March 17, 2015Assignees: Isis Pharmaceuticals, Inc., Cold Spring Harbor LaboratoryInventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger
-
Patent number: 8906873Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.Type: GrantFiled: September 10, 2010Date of Patent: December 9, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin